Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bacterial vaginosis

Bacterial vaginosis

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bacterial vaginosis

30 trials tracked for Bacterial vaginosis: 15 in phase 3 or 4 and 2 with published results. The most-cited published study has 79 citations.

30Trials tracked
15Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 5 Phase 3 10 Phase 2 7 Phase 1 1 Other / NA 7
  1. Phase 3 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis Completed · 79 cited
  2. Phase 3 DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) Completed · 11 cited
  3. Phase 4 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Completed
  4. Phase 4 Probiotics as Adjuvant Treatment for Bacterial Vaginosis Completed
  5. Phase 4 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Completed
  6. Phase 4 Treatment of Bacterial Vaginosis (BV) With Tinidazole Completed
Show 24 more trials
  1. Phase 4 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study Completed
  2. Phase 3 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed
  3. Phase 3 Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Completed
  4. Phase 3 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed
  5. Phase 3 Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis Completed
  6. Phase 3 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women Completed
  7. Phase 3 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed
  8. Phase 3 Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219 Completed
  9. Phase 3 Bacterial Vaginosis Home Screening to Prevent STDs Completed
  10. Phase 2 A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis Completed
  11. Phase 2 Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition Completed
  12. Phase 2 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed
  13. Phase 2 LACTIN-V Study for Recurrent Bacterial Vaginosis Completed
  14. Phase 2 Suppression Of Bacterial Vaginosis (BV) [SUBVert] Completed
  15. Phase 2 Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV) Completed
  16. Phase 2 Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis Completed
  17. Phase 1 Safety Study of Lactobacillus Administered Vaginally to Healthy Women Completed
  18. N/A Rwanda Vaginal Microbiota Restoration Study Completed
  19. N/A Women's Improvement of Sexual Health (WISH) Demonstration Project Completed
  20. N/A A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test Completed
  21. N/A Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis Completed
  22. N/A Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial Completed
  23. N/A Point of Care Diagnosis of Vaginal Infections Completed
  24. N/A Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bacterial vaginosis: what the trials found

Several pharmacological interventions have been evaluated for the treatment of bacterial vaginosis (BV). Metronidazole has been studied in both oral and other forms, with evidence showing that oral metronidazole significantly reduced patient-reported symptoms compared to controls 15. Additionally, trials involving metronidazole and tinidazole were conducted to assess efficacy 6, and a study on metronidazole showed a median time of 14 days to BV recurrence following the cessation of therapy 5.

Topical treatments have demonstrated varying degrees of clinical success. Clindamycin phosphate vaginal cream (2%) was evaluated for both clinical and bacteriological cure (Nugent Score <4) 11, while clindamycin phosphate vaginal gel (2%) was also studied as a specific intervention 8. Other topical agents, including GDC-229 12 and 1% SPL7013 Gel [13, 14], showed significant clinical cure rates compared to controls.

The efficacy of SYM-1219 has been evaluated in multiple trials; results indicated a reduction in Nugent scores [9, 10, 22]. Other topical interventions included Trimo-San gel 7 and the antibiotic clindamycin (as an unspecified form) which showed changes in the presence of vaginal symptoms based on Sobel Scores 4.

Recent results — preliminary, needs further review

  • The Xpert® Xpress MVP test was evaluated, showing significant results for the number of participants prescribed appropriate treatment and those receiving a correct diagnosis of vaginitis (p=<.001), though no statistically significant difference was found in the resolution of symptoms (p=.323) 1.

For the clinician treating this condition

  • Metronidazole remains a primary intervention, with oral administration shown to reduce patient-reported symptoms and show a specific timeframe for recurrence post-treatment [5, 15].
  • Multiple topical agents, including clindamycin phosphate (cream or gel), GDC-229, and SPL7013 Gel, have demonstrated statistically significant clinical cure rates in various trials [11, 12, 13, 14].
  • SYM-1219 has been shown to effectively lower Nugent scores in patients with bacterial vaginosis [9, 22].

AI synthesis of 9 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic Review Finds No BV Recurrence Reduction With Male Partner Treatment
Infectious Disease Meta-analysis
Systematic Review Finds No BV Recurrence Reduction With Male Partner Treatment Combined treatment does not lower bacterial vaginosis recurrence rates
This systematic review and meta-analysis of 953 couples found that treating male sexual partners of women with bacterial vaginosis did not s…
A large review of 953 couples found that treating male partners alongside women did not reduce bacterial vaginosis recurrence compared to tr…
May 1, 2026
Virome and mycobiome roles in female reproductive tract health are increasingly recognized as potential ecosystem modulators
Allergy & Immunology Sys. Review
Virome and mycobiome roles in female reproductive tract health are increasingly recognized as potential ecosystem modulators Viruses and Fungi Hold the Key to Vaginal Health
This systematic scoping review examined the impact of the virome and mycobiome on female reproductive tract health compared to a bacteriocen…
Doctors need to look at the whole microbial team, not just the bacteria, to fix vaginal infections.
Frontiers Apr 12, 2026
Phase 1 trial shows vaginal L. crispatus biotherapeutics colonize in bacterial vaginosis patients
Infectious Disease RCT
Phase 1 trial shows vaginal L. crispatus biotherapeutics colonize in bacterial vaginosis patients A Simple Swab Could Stop Bacterial Vaginosis From Coming Back
A phase 1 randomized trial in 71 participants with bacterial vaginosis in the US and South Africa tested vaginally delivered multi-strain La…
For the millions who struggle with BV that keeps returning, this early research points to a promising new strategy: using beneficial bacteri…
Apr 11, 2026
Intravaginal vitamin C may increase short-term cure and prevent recurrence of bacterial vaginosis
Infectious Disease Meta-analysis
Intravaginal vitamin C may increase short-term cure and prevent recurrence of bacterial vaginosis Intravaginal Vitamin C May Help Treat Bacterial Vaginosis in Nonpregnant Patients
A meta-analysis of 1,107 nonpregnant patients found intravaginal vitamin C (250 mg daily for 6 days) was associated with higher short-term c…
Intravaginal vitamin C cured 66% of bacterial vaginosis patients in short-term trials, outperforming placebo and showing promise against sta…
Apr 9, 2026

Questions about Bacterial vaginosis

Can male partner treatment significantly reduce bacterial vaginosis recurrence?

A 2024 systematic review found that treating male partners does not significantly reduce bacterial vaginosis recurrence compared to treating women alone, though adherence to medication by partners may offer some benefit.

Full answer →